局部晚期宫颈癌组织中LAPTM4B的表达与新辅助化疗疗效及预后的关系

Objectives: LAPTM4B (lysosomal protein transmembrane-4 beta) plays a critical role in tumor progression and chemoresistance. The aim of this study was to evaluate the significance of LAPTM4B expression to predict response to platinum-based neoadjuvant chemotherapy and survival of patients with locally advanced cervical cancer (LACC) who subsequently underwent radical hysterectomy. Materials and methods: Biopsy specimens of cervical cancer before neoadjuvant chemotherapy were obtained from 116 patients who subsequently underwent radical hysterectomy. The expression of LAPTM4B protein was analyzed by immunohistochemistry. Findings were evaluated in relation to LAPTM4B expression and chemotherapy resistance. Survival analyses were performed by the Kaplan-Meier curves and a Cox regression model to determine overall survival (OS) and disease-free survival (DFS). Results: Our result showed that LAPTM4B was highly expressed in 73.3% of LACC sections. Expression of LAPTM4B was significantly associated with poor clinical response (P=0.012). Moreover, high expression of LAPTM4B was significantly associated with poor OS and DFS compared with the low expression group (both P<0.05). Multivariate analysis revealed that LAPTM4B expression was an independent prognostic factor for OS (P<0.05). Conclusions: In conclusion, elevated LAPTM4B expression in patients with locally advanced cervical cancer contributes to chemoresistance and predicts poor prognosis.